Node.js released updates fixing a critical DoS flaw caused by async_hooks stack crashes, tracked as CVE-2025-59466, impacting ...

Fractional-order systems have proven to be useful to well model diffusion or propagation phenomena. Recursive or online system identification of continuous-time fractional models is explored in this ...

This is meant to be used with the crosshair overlay module for https://recursiontracker.com/ Finding the crosshair path and where to put it is in the Installation ...

Abstract: Many recent image restoration methods use Transformer as the backbone network and redesign the Transformer blocks. Differently, we explore the parameter-sharing mechanism over Transformer ...

Jandas is designed to have very similar indexing experience as Pandas. It implements DataFrame, Series and Index classes in TypeScript and supports position- and label-based indexing. Unlike Pandas ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best fundamentally strong penny stocks to buy according to analysts. On December 19, TheFly reported that Cathie Wood’s ARK Investment has ...

Cathie Wood’s ARK ETF published their daily trades for Friday, December 19th, 2025, showcasing significant activity in several key stocks. Leading the trades was a substantial sale of 23,110 shares of ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Recursion Pharmaceuticals, Inc. (RXRX) recently received a notable upgrade from JP Morgan analyst Eric Joseph, who shifted his rating to “Overweight” on December 17, 2025. This upgrade comes as the ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from ...